Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial
An erratum to this article was published (JAMA Netw Open, 1 May 2026 ↗)
Primary resultResult — go to the resultRelative risk 0.94 95% CI 0.76–1.17- terminated prematurely
- Terminated prematurely due to low enrollment rates
Authors' conclusion
In this randomized clinical trial of patients with septic shock, albumin administration was safe but did not improve 90-day survival.
Study context
- Population
- Patients enrolled within 24 hours of septic shock onset, 23 ICUs in Germanyrandomized
- Participants
- 440 patients
- Comparison
- 20% albumin vs standard crystalloid fluids
- Albuminn = 222
- Controln = 218reference
- Primary endpoint
- Mortality
- Follow-up
- Up to 90 days
Methodological detailsmulticentre, open-label
- Multicentre
- Open-label
Primary result
As reported in the abstract
Relative risk
0.94
95% CI 0.76–1.17
P = 0.71
Events by treatment group
Albumin vs Control
RR 0.94 (95% CI 0.76–1.17); P = 0.71
Secondary outcomes
Secondary end points (28-day, 60-day, ICU and in-hospital mortality, organ dysfunction, fluids, LOS, adverse events)
- No significant differences
Original publication
Albumin Replacement Therapy in Septic Shock: A Randomized Clinical Trial. JAMA Netw Open. Published 2 February 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →